Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Small Intestine Cancer. According to GlobalData, Phase I drugs for Small Intestine Cancer have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ropidoxuridine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ropidoxuridine overview
Ropidoxuridine is under development for the treatment of sarcoma, glioblastoma and gastrointestinal cancers (GI cancers) including cancers of the esophagus, liver, stomach, small bowel, pancreas, bile duct, colon or rectum. It is an orally available prodrug radiation sensitizer.
Shuttle Pharmaceuticals overview
Shuttle Pharmaceuticals (Shuttle) is a developer of therapies that offer novel drugs for improving cancer treatment outcomes. The company’s pipeline products comprise therapies such as Ropidoxuridine (IPdR) and doranidazole. Its therapies are used to improve the outcomes of patients receiving radiation therapy for the treatment of various types of cancers such as rectal cancer, lung, pancreatic and hematologic cancers. Shuttle’s products are used to sensitize cancer cells, protect normal tissues and monitor clinical responses to treatment. The company also discovers and develops novel small molecules and modifies the effects of ionizing radiations. Shuttle is headquartered in Gaithersburg, Maryland, the US
For a complete picture of Ropidoxuridine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
